HK Inno.N announced on the 6th that it has launched K-Cab (ingredient name tecopramine), a new drug for gastroesophageal reflux disease, in Australia and New Zealand.
K-Cab, the 30th new drug developed in South Korea, is a gastroesophageal reflux disease treatment in the potassium competitive acid secretion inhibitor (P-CAB) class. It is characterized by its rapid efficacy, appearing within one hour after ingestion, and its proven effectiveness and safety for long-term use up to six months.
HK Inno.N recently signed a finished goods export contract for K-Cab tablets with Australian pharmaceutical company Southern XP for Australia and New Zealand. Under this contract, Southern XP will hold exclusive distribution and sales rights for K-Cab. The products include K-Cab 50 mg and K-Cab 25 mg.
The pharmaceutical market in Australia and New Zealand is approximately 22 trillion won as of 2023, with the market for digestive ulcer agents reaching about 150 billion won.
To date, K-Cab has entered 48 countries worldwide, including the United States, China, and South Korea, and has been launched in 15 countries. In South Korea, it recorded a total of 177.7 billion won in outpatient prescriptions from January to November 2024, maintaining its position as the number one digestive ulcer agent in the domestic market for five consecutive years.
Kwak Dal-won, CEO of HK Inno.N, noted, "K-Cab is being recognized for its value as a new drug from South Korea even in overseas countries, steadily expanding its influence in the global digestive ulcer agent market. We aim to strengthen K-Cab's global competitiveness with the goal of entering 100 countries by 2028."